Solid Biosciences (SLDB) Invested Capital (2017 - 2026)

Solid Biosciences has disclosed Invested Capital across 10 years of filings, most recently posting $377.5 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $377.5 million, up 26.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $377.5 million (up 26.14% YoY), and the FY2025 annual result was $189.2 million, up 34.77% from the prior year.
• Invested Capital came in at $377.5 million for Q1 2026 at Solid Biosciences, up from $189.2 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $377.5 million in Q1 2026 to a low of $126.5 million in Q4 2023.
• The 5-year median for Invested Capital is $185.5 million (2022), against an average of $199.4 million.
• Across the five-year window, Invested Capital tumbled 40.25% in 2023 and surged 42.02% in 2025, its largest moves.
• Solid Biosciences' Invested Capital stood at $211.7 million in 2022, then sank by 40.25% to $126.5 million in 2023, then advanced by 11.0% to $140.4 million in 2024, then jumped by 34.77% to $189.2 million in 2025, then jumped by 99.5% to $377.5 million in 2026.
• The last three Invested Capital figures came in at $377.5 million (Q1 2026), $189.2 million (Q4 2025), and $224.5 million (Q3 2025), per Business Quant data.